Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


MabCampath Warning Issued After Deaths

Nov 24, 2008 | Parker Waichman LLP

Canadian health authorities are warning that MabCampath, a drug used to treat leukemia, has been linked to infection-related deaths.  According to Health Canada, researchers conducting  a clinical trial in the United States have reported six such deaths among MabCampath patients.  

MabCampath, marketed by Bayer HealthCare and Genzyme,  is used after other drugs to treat  B-cell chronic lymphocytic leukemia have been unsuccessful.  It is one of  a new group of cancer drugs known as monoclonal antibodies. Monoclonal antibodies recognize certain proteins that are found on the surface of some types of cancer cells. This may then trigger the body’s immune system to attack the cancer cells and cause the cells to destroy themselves.

MabCampath can reduce the production of white blood cells by the bone marrow.  This may make some patients more prone to bacterial and viral infection. This risk is usually at its highest during MabCampath treatment and for about two months afterwards

Researchers conducting  a clinical trial in the United States  reported six infection-related deaths out of 51 patients.  The deaths occurred among patients who were taking immune system-suppressing anti-leukemia drugs, followed by MabCampath.  The six fatal infections were due to either bacteria, viruses or fungus, Health Canada said.

Health Canada pointed out that a number of factors could have increased the risk of infection associated with this use of MabCampath.  These may include the specific initial treatment plan, dose of drugs used, and the time interval between initial combination therapy followed by the use of MabCampath.

All three drugs used in the study  are known to reduce the activity of the immune system which makes the treated individual more susceptible to infection, Health Canada said.


Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo